目的观察并探讨曲美他嗪联合麝香保心丸治疗不稳定型心绞痛临床效果及安全性。方法选取我院2009年7月至2012年1月收治不稳定型心绞痛患者170例,采用随机数字表法分为两组,其中对照组85例,采用绝对静卧休息,β受体阻滞剂,他汀类药物及阿司匹林等常规抗心绞痛治疗,实验组85例,在对照组治疗基础上,加用曲美他嗪,15mg/次,3次/d,麝香保心丸2粒/次,3次/d联合治疗;疗程均为4周;比较两组患者临床症状改善总有效率,心电图改善总有效率,治疗前后心绞痛发作次数、持续时间,血液流变学指标及不良反应发生率等。结果实验组患者临床症状改善总有效率明显高于对照组,组间比较差异有统计学意义(P<0.05);实验组患者心电图改善总有效率明显高于对照组,组间比较差异有统计学意义(P<0.05);治疗后两组患者心绞痛发作次数及持续时间均明显下降,且实验组患者下降程度明显高于对照组,组间比较差异有统计学意义(P<0.05);治疗后两组患者全血比粘度及血浆比粘度均明显下降,且实验组患者下降程度明显高于对照组,组间比较差异有统计学意义(P<0.05);同时两组患者不良反应发生率组间比较差异无统计学意义(P>0.05)。结论曲美他嗪联合麝香保心丸治疗不稳定型心绞痛临床效果满意,能够有效改善患者临床症状,缓解心绞痛发作,且无严重不良反应,可作为临床首选治疗手段。 Objective To observe and discuss the clinical efficacy and safety of trimetazidine combined with Shexiang Baoxin Pill in the treatment of unstable angina pectoris. Methods A total of 170 patients with unstable angina pectoris admitted from July 2009 to January 2012 in our hospital were divided into two groups according to the random number table. Among them, 85 patients in the control group were treated with absolute rest, β-blockers , Statins and aspirin and other conventional anti-angina treatment, the experimental group of 85 patients on the basis of the control group, plus trimetazidine, 15mg / time, 3 times / d, musk pill 2 / Times / d combination therapy; the course of treatment was 4 weeks. The total effective rate of clinical symptom improvement, the total effective rate of ECG improvement, the number of angina attacks before and after treatment, duration, hemorheological indexes and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of clinical symptom improvement in experimental group was significantly higher than that in control group, with significant difference between the two groups (P <0.05). The total effective rate of ECG in experimental group was significantly higher than that in control group with statistically significant difference (P0.05) .After treatment, the number and duration of angina pectoris in both groups were significantly decreased, and the degree of decline in the experimental group was significantly higher than that in the control group, the difference was statistically significant (P 0.05); treatment The latter two groups of patients with whole blood viscosity and plasma viscosity were significantly decreased, and the decline in the experimental group was significantly higher than the control group, the difference between the two groups was statistically significant (P <0.05); the incidence of adverse reactions in both groups of patients There was no significant difference between the two groups (P> 0.05). Conclusions Trimetazidine combined with Shexiang Baoxin Pill has satisfactory clinical effect in treating unstable angina pectoris. It can effectively improve clinical symptoms and relieve angina pectoris without serious adverse reactions, which can be used as the first choice of clinical treatment.